Skip to main content
Advertisement
Advertisement

PCVX

PCVX logo

Vaxcyte, Inc. Common Stock

65.02
USD
Sponsored
-1.94
-2.90%
Oct 08, 15:59 UTC -4
Closed
exchange

After-Market

65.17

+0.16
+0.24%

PCVX Earnings Reports

Positive Surprise Ratio

PCVX beat 13 of 25 last estimates.

52%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$2.17
Implied change from Q2 26 (Revenue/ EPS)
--
/
+10.15%
Implied change from Q3 25 (Revenue/ EPS)
--
/
+39.10%

Vaxcyte, Inc. Common Stock earnings per share and revenue

On Aug 05, 2026, PCVX reported earnings of -1.97 USD per share (EPS) for Q2 26, beating the estimate of -2.09 USD, resulting in a 6.04% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -2.17 USD, with revenue projected to reach -- USD, implying an increase of 10.15% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
logo
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
logo
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
logo
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
logo
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
FAQ
For Q2 2026, Vaxcyte, Inc. Common Stock reported EPS of -$1.97, beating estimates by 6.04%, and revenue of $0.00, 0% as expectations.
The stock price moved up 5.31%, changed from $55.92 before the earnings release to $58.89 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 7 analysts, Vaxcyte, Inc. Common Stock is expected to report EPS of -$2.17 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement